Julie Rubinstein, President and Chief Operating Officer of Adaptive Biotechnologies Corp, filed a Form 4 on November 3, 2026, disclosing option exercises and common stock sales executed between October 30 and November 3, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT)
  • Trading plan: All transactions were effected pursuant to a Rule 10b5-1 plan adopted on November 18, 2025
  • Options exercised: 11,881 shares acquired on each of October 30, November 2, and November 3, 2026, at an exercise price of $12.14 per share
  • Shares sold: A total of 35,643 shares of common stock disposed of across the three trading dates at weighted average prices ranging from approximately $25.23 to $27.45
  • Remaining beneficial ownership: 377,802 shares of common stock directly held following all reported transactions
  • Remaining options: 94,633 stock options (right to buy) remaining directly held after the three exercises, with an expiration date of March 4, 2032

Rubinstein's Three-Day Option Exercise and Share Sale Activity at Adaptive Biotechnologies

According to the filing, Julie Rubinstein exercised stock options and sold shares of Adaptive Biotechnologies Corp common stock on three consecutive trading days. On each of October 30, November 2, and November 3, 2026, she acquired 11,881 shares via exercise of a stock option (transaction code M) at an exercise price of $12.14 per share. The filing notes the options are "fully vested and exercisable" and carry an expiration date of March 4, 2032.

On October 30, 2026, Rubinstein sold 9,486 shares at a weighted average price of $26.55 (ranging from $26.20 to $27.07) and 2,395 shares at a weighted average price of $27.45 (ranging from $27.21 to $27.98). On November 2, 2026, she sold 9,296 shares at a weighted average price of $25.23 (ranging from $24.88 to $25.86) and 2,585 shares at a weighted average price of $26.34 (ranging from $25.91 to $26.81). On November 3, 2026, she sold 11,881 shares at a weighted average price of $25.98 (ranging from $25.65 to $26.43). All sale prices reported are weighted averages across multiple transactions within each range, as disclosed in the filing's footnotes.

The filing states that all transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Rubinstein on November 18, 2025. Following all reported activity, Rubinstein directly held 377,802 shares of common stock and 94,633 stock options. The filing was signed by Kyle Piskel as attorney-in-fact on November 3, 2026.

What Was Disclosed

Rubinstein's Form 4 covers eight common stock transactions and three option exercises between October 30 and November 3, 2026, all conducted under a pre-established 10b5-1 plan, leaving her with 377,802 directly held shares and 94,633 remaining options.